EGFR overexpression and radiation response in glioblastoma multiforme

International Journal of Radiation Oncology Biology Physics

Volumn 51, Issue 2, 2001, Pages 410-418

  Barker II, Fred G ^a,b   Simmons, Martha L ^a   Chang, Susan M ^a   Prados, Michael D ^a   Larson, David A ^c   Sneed, Penny K ^c   Wara, William M ^c   Berger, Mitchel S ^a   Chen, Pengchin ^a   Israel, Mark A ^a   Aldape, Ken D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epidermal growth factor receptor; Glioblastoma multiforme; p53; Radiosensitivity

Indexed keywords

GENETIC ENGINEERING; RADIATION; RADIOGRAPHY; TUMORS;

EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR);

ONCOLOGY;

CARMUSTINE; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR; HYDROXYUREA; PROTEIN P53;

AGE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOSENSITIVITY; REVIEW;

EID: 0035479296     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01609-1     Document Type: Article

References (81)

1. Radiation response and survival in patients with glioblastoma multiforme
2. Age and treatment response in glioblastoma multiforme (GM)
3. EGF receptor amplification, and expression in human brain tumours
4. Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis
5. Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas; An analysis of 168 cases
6. Alterations of the TP53 gene in human gliomas
7. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations
8. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors
9. Phase III trial of accelerated hyperfractionation with or without difluoromethylornithine (DFMO) versus single fraction radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme
10. Grading of gliomas
11. Correlation of survival and diagnosis in supratentorial malignant gliomas
12. Analysis of complex relationships between age, p53, EGFR, and survival in glioblastoma patients
13. Validation of fluorescent SSCP analysis for sensitive detection of p53 mutations
14. Constitutional p53 mutations associated with brain tumors in young adults
15. Analyzing data from ordered categories
16. Collapsing ordered outcome categories; a note of concern
17. Imaging response is highly predictive of survival of malignant glioma patients treated with standard or hyperfractionated RT and carmustine in RTOG 9006
18. Molecular genetics of gliomas
19. Genetic alterations in adult diffuse glioma; occurrence, significance, and prognostic implications
20. Gene amplification in human gliomas
21. Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis
22. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas
23. MDM2, and p53 expression in gliomas; A multivariate survival analysis including proliferation markers and epidermal growth factor receptor
24. Gene amplification as a prognostic factor in primary brain tumors
25. Prognostic factors in malignant glioma; Influence of the overexpression of oncogene and tumor-suppressor gene products on survival
26. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma
27. Epidermal growth factor receptor; An independent predictor of survival in astrocytic tumors given definitive irradiation
28. Amplification, enhanced expression, and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin
29. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling
30. Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue
31. The epidermal growth factor receptor in glioblastoma; Genomic amplification, protein expression, and patient survival data in a therapeutic trial
32. Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome
33. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours
34. Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs)
35. Amplification of epidermal growth factor receptor gene in gliomas; Histopathology and prognosis
36. Relationships between Ki-67 labelling index, amplification of the epidermal growth factor receptor gene, and prognosis in human glioblastomas
37. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens
38. Clinical evidence of distinct subgroups of astrocytic tumors defined by comparative genomic hybridization
39. Genetic characterization of the EGFR amplicons in glioblastoma multiforme
40. The p53 gene and protein in human brain tumors
41. The challenge of p53 as prognostic and predictive factor in gliomas
42. Comparative study of p53 gene and protein alterations in human astrocytic tumors
43. p53 status has no prognostic significance in glioblastomas treated with radiotherapy
44. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin; Relationships and prognostic value
45. Prognostic significance of p53 immunoreactivity in patients with glioma
46. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes
47. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas
48. p53 gene mutation, and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma
49. The prognostic impact of prior low grade histology in patients with anaplastic gliomas; A case-control study
50. Primary and secondary glioblastomas; From concept to clinical diagnosis
51. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme
52. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas
53. Molecular genetics of radiographically defined de novo glioblastoma multiforme
54. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas
55. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas
56. Tumour-proliferative fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix
57. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas
58. Correlation of epidermal growth factor receptor and radiosensitivity in human maxillary carcinoma cell lines
59. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck
60. Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures
61. Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro
62. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers
63. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas; Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis
64. The effect of ionizing radiation on signal transduction; antibodies to EGF receptor sensitize A431 cells to radiation
65. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
66. Radiosensitization of malignant glioma cells through overexpression of a dominant negative EGFR-CD533
67. Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells
68. The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells
69. Dominant negative EGFR-CD533, and inhibition of MAPK modify JNK1 activation, and enhance radiation toxicity of human mammary carcinoma cells
70. Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling, and glioblastoma phenotype by signal-regulatory proteins (SIRPs)
71. p53-dependent G1 arrest, and p53-independent apoptosis influence the radiobiologic response of glioblastoma
72. Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells
73. The intrinsic radioresistance of glioblastoma-derived cell lines is associated with a failure of p53 to induce p21-BAX expression
74. Bromodeoxyuridine labeling index in glioblastoma multiforme; Relation to radiation response, age, and survival
75. Chromosomal abnormalities in glioblastoma multiforme by comparative genomic hybridization; correlation with radiation treatment outcome
76. Correlation between radiation response and genetic aberrations in glioblastoma multiforme
77. Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytoma
78. Correlation of tumor p53 and PCNA with response and survival of glioblastoma in patients treated with an ECOG protocol of pre-irradiation chemotherapy